Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation

🚨Publication Alert 🚨
Your Wednesday read this week comes from Dr. Huali Wu, Director of Pharmacometrics at Amador and the American College of Clinical Pharmacy (ACCP).

📃 Read it here: https://hubs.la/Q01zN0BV0

Hydrochlorothiazide (HCTZ) is a thiazide diuretic used in adults and children for the treatment of hypertension and edema. The pharmacokinetic (PK) properties of HCTZ in children are not well characterized, particularly among children with obesity which is particularly relevant given the frequent comorbid occurrence of hypertension with obesity.

To address these knowledge gaps, Dr. Huali Wu together with an expert team, conducted a pediatric population PK study of HCTZ in a cohort of infants and children across a wide range of ages and body weights. Population PK modeling was performed using a non-linear mixed-effects modeling software package model leveraged to conduct dose-exposure simulations with a standardized 1mg/kg.

The results showed that simulated exposure, area under the curve and maximum HCTZ concentrations decreased with age, the authors suggesting that this was likely due to older children receiving the maximum absolute doses of HCTZ. Further studies with more patients in each age group are required to confirm these new and relevant PK findings of HCTZ in the children.

This PK study across a wide range of ages and body weights in infants and children is a major contribution in the understanding of the PK properties of HCTZ allowing to adjust dosing in children for the treatment of hypertension and obesity.

Want to learn more?